Screener
Sana Biotechnology SANA Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216769
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| TOTAL ASSETS | $373,593 | $416,890 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $2,123 | $1,669 |
| Accrued compensation | 7,584 | 13,240 |
| Accrued expenses and other current liabilities | 8,124 | 8,679 |
| Operating lease liabilities | 14,878 | 14,938 |
| Contingent consideration | 53,556 | 40,200 |
Item 1. Financial Statements
FAQ
- What is Sana Biotechnology's accounts payable?
- Sana Biotechnology (SANA) reported accounts payable of $2.12M in Q1 2026.
- How has Sana Biotechnology's accounts payable changed year-over-year?
- Sana Biotechnology's accounts payable increased by 114.7% year-over-year, from $989K to $2.12M.
- What is the long-term trend for Sana Biotechnology's accounts payable?
- Over 4 years (2021 to 2025), Sana Biotechnology's accounts payable has grown at a -16.8% compound annual growth rate (CAGR), from $14.13M to $6.79M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Sana Biotechnology's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude